Who Will Get First AD Drug To Market In Over A Decade?
This article was originally published in Scrip
Alzheimer's disease (AD) drug developer Axovant Sciences, which earlier this year raised a record-breaking sum of cash, has launched a large Phase III study for its 5-HT6 receptor antagonist, RVT-101– a move it hopes will set the company up to seek the first approval for any new AD product in over a decade.
You may also be interested in...
Presentation of data at Alzheimer’s Association International Conference highlights failure of Pfizer’s 5HT6 antagonist PF-05212377, while still leaving room to hope for others in class like Lundbeck’s idalopirdine and Axovant’s RVT-101
For In Vivo's 13th annual Deals of the Year contest, we selected 15 nominees in three categories – Top Alliance, Top Financing and Top M&A. The polls are closed, and it is time to reveal the winners.
A new technology accelerator, FemTech Lab, will support the scale-up of at least 10 firms in 2021 that have innovative solutions for issues affecting women’s health and wellbeing. The founders talk to In Vivo about their view of the femtech market and how it will impact traditional health care.